Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…, 3

In forcesince 31 Dec 2020

…

Changed on 31 Dec 2020

1. No medicinal product appearing in the Annex may be placed on the market within the Union unless a marketing authorisation has been granted by the Union in accordance with the provisions of this Regulation. 2. Any medicinal product not appearing in the Annex may be granted a marketing authorisation by the Union in accordance with the provisions of this Regulation, if: (a) the medicinal product contains a new active substance which, on the date of entry into force of this Regulation, was not authorised in the Union; or (b) the applicant shows that the medicinal product constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorisation in accordance with this Regulation is in the interests of patients or animal health at Union level. Immunological veterinary medicinal products for the treatment of animal diseases that are subject to Union prophylactic measures may also be granted such authorisation. 3. A generic medicinal product of a reference medicinal product authorised by the Union may be authorised by the competent authorities of the Member States in accordance with Directive 2001/83/EC and Directive 2001/82/EC under the following conditions: (a) the application for authorisation is submitted in accordance with Article 10 of Directive 2001/83/EC or Article 13 of Directive 2001/82/EC; (b) the summary of the product characteristics is in all relevant respects consistent with that of the medicinal product authorised by the Union except for those parts of the summary of product characteristics referring to indications or dosage forms which were still covered by patent law at the time when the generic medicine was marketed; and (c) the generic medicinal product is authorised under the same name in all the Member States where the application has been made. For the purposes of this provision, all the linguistic versions of the INN (international non-proprietary name) shall be considered to be the same name. 4. After the competent committee of the Agency has been consulted, the Commission may adapt the Annex to technical and scientific progress and may adopt any necessary amendments without extending the scope of the centralised procedure. Those measures, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 87(2a).…

  1. 31 Dec 2020 – todayin force
  2. 28 Jan 2019 – 31 Dec 2020earlier wording
  3. 20 Apr 2009 – 28 Jan 2019earlier wording
  4. 26 Jan 2007 – 20 Apr 2009earlier wording

Versions are held from 26 Jan 2007; the article may be older.